ASSOCIATIONS OF CIRCULATING CERAMIDE LEVELS WITH BODY MASS INDEX AND LIVER FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE

Main Article Content

Murodjon Adahamjon o‘g‘li Nasirdinov, Zuhriddin Salohiddinovich Salohiddinov

Abstract

Background and aims. Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by metabolic dysfunction-associated steatotic liver disease (MASLD), is closely linked to excess adiposity and progressive metabolic injury. Ceramides are bioactive sphingolipids implicated in insulin resistance, lipotoxicity and fibrogenic signaling. We evaluated circulating ceramide levels in relation to body mass index (BMI) and liver fibrosis. Methods. This cross-sectional study included 84 participants: 29 controls without hepatic steatosis or fibrosis and 55 patients with NAFLD (28 with steatosis and 27 with steatohepatitis). BMI was assessed anthropometrically, fasting blood was collected using a standardized protocol, ceramide was measured by a high-sensitivity spectro-chromatographic method, and fibrosis was assessed by transient elastography/FibroScan. Non-parametric comparisons used Mann-Whitney U and Kruskal-Wallis tests; ordered associations were assessed using Spearman correlation. Results. Median BMI was higher in NAFLD than controls (30.68 [IQR 6.21] vs 22.20 [2.50] kg/m2; U=13.000; Z=-7.385; p<0.001). In the NAFLD group, 12.7% had normal weight, 29.1% were overweight and 58.2% had obesity. Ceramide differed across BMI categories (H=38.356; p<0.001): 4.25 [8.54] in normal weight, 59.78 [55.57] in overweight and 59.73 [52.73] in obesity. Ceramide also differed across fibrosis stages (H=45.700; p<0.001), with mean values of 5.28+/-5.41 at F0, 30.74+/-23.74 at F1, 45.37+/-34.97 at F2, 57.80+/-23.11 at F3 and 44.17+/-26.88 at F4. Fibrosis stage correlated positively with ceramide (r=0.654; p<0.001). Conclusions. Excess body mass was accompanied by markedly higher circulating ceramide levels, and ceramide was associated with fibrosis severity. These findings support further study of sphingolipid metabolism as a metabolic marker linking adiposity and liver injury, while the cross-sectional design precludes causal inference.

Article Details

Section

Articles

References

1.Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0.

2.Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28. doi:10.1016/j.cgh.2021.12.002.

3.Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003.

4.European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.

5.Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.

6.Ng CH, Lim WH, Lim GEH, Tan DJH, Syn N, Muthiah MD, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931-939.e5. doi:10.1016/j.cgh.2022.04.014.

7.Grocic M, Nguyen M, Sanyal AJ. Current trends in the epidemiology of obesity and the association between obesity and metabolic liver disease (MASLD/MASH). Diabetes Obes Metab. 2026;28(Suppl 2):3-18. doi:10.1111/dom.70662.

8.Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157:155937. doi:10.1016/j.metabol.2024.155937.

9.Wilkerson JL, Tatum SM, Holland WL, Summers SA. Ceramides are fuel gauges on the drive to cardiometabolic disease. Physiol Rev. 2024;104(3):1061-1119. doi:10.1152/physrev.00008.2023.

10.Yu XD, Wang JW. Ceramide de novo synthesis in non-alcoholic fatty liver disease: pathogenic mechanisms and therapeutic perspectives. Biochem Pharmacol. 2022;202:115157. doi:10.1016/j.bcp.2022.115157.

11.Chen J, Hao Y, Xu P, Bian D, Han L, Wu X, et al. CerS5 deficiency promotes liver fibrosis development in non-alcoholic fatty liver disease. Biochem Biophys Res Commun. 2023;667:120-126. doi:10.1016/j.bbrc.2023.05.027.

12.Denimal D, Beland-Bonenfant S, Pais-de-Barros JP, et al. Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22:310. doi:10.1186/s12933-023-02049-2.

13.Heymann CJF, Mak AL, Holleboom AG, Verheij J, Shiri-Sverdlov R, van Mil SWC, et al. The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease. Lipids Health Dis. 2024;23(1):402. doi:10.1186/s12944-024-02380-x.

14.Beland-Bonenfant S, Denimal D, Pais-de-Barros JP, Choubley H, Rouland A, Simoneau I, et al. Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes. Diabetes Obes Metab. 2025;27(12):7490-7501. doi:10.1111/dom.70156.

15.Guerra S, Mocciaro G, Gastaldelli A. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Eur J Clin Invest. 2022;52(3):e13695. doi:10.1111/eci.13695.

16.Hagstrom H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944-956. doi:10.1016/S2468-1253(24)00193-6.

17.Chouik Y, Aubin A, Maynard-Muet M, Segrestin B, Milot L, Hervieu V, et al. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD. Obesity (Silver Spring). 2024;32(6):1114-1124. doi:10.1002/oby.24033.

18.Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559-1569. doi:10.1056/NEJMoa2029349.